Learn More >

Ministry Status: Routine Monitoring and Engagement

Patient Evidence Submissions

Drug Review Schedule

The Ontario Public Drug Program is currently accepting submissions of patient evidence on the following drug products which will undergo review by the Committee to Evaluate Drugs within the next 12 months.

Drug products on this list include new chemical entities, new combination products and existing drug products with a new indication recently approved by Health Canada. At this time, drug products that are line extensions (such as additional strengths and new dosage forms) and drug products that are undergoing reconsideration (second review, etc.) will not be considered for patient submissions. The Ministry will re-evaluate this once additional experience on the process is gained.

For drug products accepted for Rapid Review process, best efforts will be made to provide maximal time for patient submissions. However, in view of the intent of Rapid Review, the review of a drug product accepted for Rapid Review will not be held if only to include presentation of patient submissions.

Registered patient groups are invited to provide patient evidence on any of the drugs listed below.

All submissions must be received by 5:00pm of the deadline date.

Generic Name Brand Name Manufacturer Indication / Type of Review Deadline for Patient Submissions
Brigatinib Alunbrig Takeda Canada Inc. Non-small cell
lung cancer (pCODR)
May 22, 2019
Daratumumab Darzalex Janssen Inc. Multiple myeloma
(newly diagnosed) (pCODR)
May 22, 2019
Ixazomib Ninlaro Takeda Canada Inc. Multiple myeloma
(2nd-line and beyond)
(pCODR)
April 24, 2019
Doravirine Pifeltro Merck Canada Inc. HIV-1 infection (CDR) April 17, 2019
Doravirine/lamivudine/
tenofovir disoproxil fumarate
Delstrigo Merck Canada Inc. HIV-1 infection (CDR) April 17, 2019
OnabotulinumtoxinA Botox Allergan Inc. Migraine, chronic, prophylaxis (CDR [resubmission]) April 17, 2019
Pembrolizumab Keytruda Merck Canada Inc. Melanoma, advanced/metastatic,
first-line (request for funding beyond
24 months [up to 17
additional cycles])
April 17, 2019
Etanercept (biosimilar) Erelzi Sandoz Canada Inc. Psoriatic arthritis
(request to fund new indication)
March 27, 2019
Bevacizumab (biosimilar) Mvasi Amgen Canada Inc. Metastatic colorectal cancer, non-small cell lung cancer (pCODR) March 20, 2019
Cabozantinib Cabometyx Ipsen Biopharmaceuticals Canada Inc. Renal cell carcinoma (pCODR) March 20, 2019
Dacomitinib Vizimpro Pfizer Canada Inc. Non-small cell lung cancer (pCODR) March 20, 2019
Nivolumab Opdivo Bristol-Myers Squibb Canada Melanoma
(adjuvant therapy) (pCODR)
March 20, 2019
Pegfilgrastim Fulphila BGP Pharma ULC Febrile neutropenia in
non-myeloid malignancies (CDR)
March 20, 2019
Risankizumab TBD AbbVie Corporation Psoriasis, plaque, moderate to severe (CDR) March 20, 2019
Venetoclax Venclexta AbbVie Corporation Chronic lymphocytic leukemia
(in combination with rituximab)
(pCODR)
March 20, 2019
Dabrafenib &
trametinib in combination
Tafinlar &
Mekinist in combination
Novartis Pharmaceuticals Canada Inc. Melanoma with a BRAF V600
mutation, adjuvant treatment (pCODR)
February
20, 2019
Durvalumab Imfinzi AstraZeneca Canada Inc. Non-small cell lung cancer (pCODR) February
20, 2019
Enzalutamide Xtandi Astellas Pharma Canada Inc. Non-metastatic castration-resistant
prostate cancer (pCODR)
February
20, 2019
Palbociclib (with fulvestrant) Ibrance (with Faslodex) Pfizer Canada Inc. Advanced or metastatic breast cancer (pCODR) February
20, 2019
Pralatrexate Folotyn Servier Canada Inc. Peripheral T-cell lymphoma (pCODR) February
20, 2019
Sucroferric
oxyhydroxide
Velphoro Vifor Fresenius Medical Care Renal Pharma Hyperphosphatemia,
end-stage renal disease (CDR)
February
20, 2019
Telotristat ethyl Xermelo Ipsen Biopharmaceuticals Canada Inc. Carcinoid syndrome (CDR) February
20, 2019

See also:

Image:Pdf icon.gif To view PDF format files, you need to have Adobe Acrobat® Reader installed on your computer.
You can download this free software from the Adobe Web site.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation: Monday to Friday, 8:30am - 5:00pm